Acceleron Pharma Reports Third Quarter 2015 Financial and Operational Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Acceleron Pharma (XLRN) Tops Q3 EPS by 10c
November 4, 2015 7:02 AM ESTAcceleron Pharma (NASDAQ: XLRN) reported Q3 EPS of ($0.36), $0.10 better than the analyst estimate of ($0.46). Revenue for the quarter came in at $4.16 million versus the consensus estimate of $4.38 million.
For earnings history and earnings-related data on Acceleron Pharma (XLRN) click here.
... More